PANBELA THERAPEUTICS INC (PBLA)       0.2703  -0.09 (-24.71%)

0.2703  -0.09 (-24.71%)

US69833W1071 - Common Stock - After market: 0.269 0 (-0.48%)

PANBELA THERAPEUTICS INC0.2703

NASDAQ:PBLA (9/30/2022, 7:00:03 PM)-0.09 (-24.71%)

After market: 0.269 0 (-0.48%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-15 2022-08-15/amc Earnings (Next) 11-08 2022-11-08
Ins Owners 1.6% Inst Owners N/A
Market Cap 5.62M Shares 20.79M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.22
IPO 07-29 2014-07-29

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PBLA Daily chart

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

Company Info

PANBELA THERAPEUTICS INC

712 Vista Blvd # 305

Waconia MINNESOTA 55387

P: 19524791196.0

CEO: Jennifer K. Simpson

Employees: 4

Website: http://www.sunbiopharma.com/

PBLA News

News Image2 days ago - ChartmillFriday's session: gap up and gap down stocks

Let's have a look at the gap up and gap down stocks in today's session.

News Image2 days ago - Panbela Therapeutics, Inc.Panbela Announces Pricing of Approximately $6 Million Public OfferingNews Image2 days ago - Panbela Therapeutics, Inc.Panbela Announces Pricing of Approximately $6 Million Public Offering

MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company...

News Image3 days ago - Panbela Therapeutics, Inc.Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

News Image3 days ago - Panbela Therapeutics, Inc.Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaNews Image6 days ago - ChartmillThese stocks are moving in today's session

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

PBLA Twits

Here you can normally see the latest stock twits on PBLA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example